Mentholatum Deep Heat Rub
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Mentholatum Deep Heat Rub Tesco Heat Rub Deep Heat Heat Rub Boots Muscle Pain Relief Cream
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
12.80% w/w 5.91% w/w
1.97% w/w 1.47% w/w
Methyl salicylate Levomenthol or Racementhol Eucalyptus oil Turpentine oil For excipients see 6.1
3 PHARMACEUTICAL FORM
Cutaneous cream.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
For the symptomatic relief of:
Muscular pains and stiffness, including backache, sciatica, lumbago, fibrositis, rheumatic pain, chilblains, bruises and sprains including those caused by minor sports injuries.
4.2 Posology and method of administration
For adults and children over 5 years For topical administration.
Directions for use: - apply a thin layer to the affected part with gentle massage 2 to 3 times daily.
Can be used before or after exercise.
4.3 Contraindications
Hypersensitivity to any of the ingredients.
Hypersensitivity to aspirin, ibuprofen or other non-steroidal anti-inflammatory drugs (including when taken by mouth) especially where associated with a history of asthma.
4.4. Special warnings and precautions for use
Pregnancy and breast-feeding - avoid use unless necessary (see section 4.6).
Asthma - caution is required as salicylates may provoke bronchospasm in patients with asthma (see section 4.3).
Interactions - salicylates can increase the effect of anticoagulants and antiplatelet medications (see section 4.5).
The label/leaflet will include the following:
Do not use if you are allergic to any of the ingredients or painkillers such as aspirin, ibuprofen and other NSAIDs. Consult your doctor before use if you are pregnant, breast-feeding, asthmatic or on any prescribed medicines. For external use and only on unbroken skin. Avoid contact with the eyes and sensitive areas of skin. Always try on a small area first. Some people may experience discomfort particularly those with sensitive skin or if used in hot weather or after a bath. Not for use with occlusive dressings. Wash hands immediately after use. Discontinue use if excessive irritation or other unwanted effects occur. If symptoms persist consult your doctor. Not to be used on children under 5 years of age. Keep all medicines out of the reach and sight of children.
4.5 Interaction with other medicinal products and other forms of interaction
Although no adequately controlled interaction studies have been undertaken, it is possible that excessive use of topical salicylates may increase the effect of coumarin anticoagulants and antiplatelet medications. Patients who are taking coumarin anticoagulants or antiplatelet medications, including aspirin, should therefore exercise caution.
4.6 Pregnancy and lactation
There are no adequate data from the use of this product during pregnancy or breastfeeding upon which to base specific advice. Salicylates are aspirin-like substances; therefore similar cautions as appropriate for aspirin are advised. As with all medicinal products, use during pregnancy or breast-feeding should be avoided unless considered necessary.
4.7 Effects on ability to drive and use machines
None known.
4.8 Undesirable effects
It is possible that skin burns, blisters and temporary skin reactions such as redness, burning sensation and rashes may occur.
Reporting of suspected adverse reactions:
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme www.mhra.gov.uk/yellowcard .
4.9 Overdose
Overdose is unlikely when used as recommended. If applied to a large area of skin, or in the unlikely event of oral ingestion, the product may cause systemic adverse effects depending on the amount absorbed.
Treatment of overdose should be supportive and symptomatic.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Methyl salicylate is an aspirin like drug used for pain relief. Turpentine oil and Eucalyptus oil acts as rubefacients. Menthol when applied topically provides analgesia.
5.2 Pharmacokinetic properties
The product is for topical administration. No absorption studies have been carried out with this product. Data from the published literature on the active ingredients can be summarised as follows:
Methyl salicylate is readily absorbed form topical preparations and this absorption is enhanced by heat, exercise, occlusion and disruption to the skin surface. Rapid local hydrolysis to salicylic acid in tissues results in low systemic plasma concentrations of methyl salicylate after topical application. Topical application of methyl salicylate is therefore likely to exert local effects only. Systemic salicylic acid becomes extensively protein bound in an inactive form and the free active form is metabolised or excreted unchanged in the urine.
Pharmacokinetic information following topical application of menthol is limited. Menthol is absorbed, across the skin with relatively low systemic plasma concentrations indicating that the effects of topical menthol are likely to be predominantly local in nature. There is thought to be some metabolism of topical menthol in the skin, but the majority is metabolised by the liver which converts the lipid soluble menthol into four water soluble metabolites that are excreted in the urine.
Very little is known about the pharmacokinetic properties of eucalyptus and turpentine oils following topical application.
5.3 Preclinical safety data
No toxicology testing of the product has been undertaken. However, all the active ingredients are subject to monographs in the British and European Pharmacopoeias and are documented in Martindale, The Complete Drug Reference.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Sodium cetostearyl sulphate
Cetostearyl alcohol Propylene glycol Wool fat (Lanolin)
Liquid paraffin Water
6.2 Incompatibilities
Not applicable.
6.3 Shelf life
3 years.
6.4 Special precautions for storage
Store below 25oC.
6.5 Nature and contents of container
Aluminium tube filled to an average weight of 35g, 42g, 67g or 100g with a high density polyethylene cap enclosed by a cardboard carton.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal
None.
7 MARKETING AUTHORISATION HOLDER
The Mentholatum Company Limited
1 Redwood Avenue
Peel Park Campus
East Kilbride
G74 5PE
Scotland
United Kingdom
8 MARKETING AUTHORISATION NUMBER(S)
PL 00189/5002R
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
24 January 1995
10 DATE OF REVISION OF THE TEXT
11/02/2015